Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL
CHICAGO — Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic analysis. Alexander Dean Sherry, MD of the MD Anderson Cancer Center in Houston, and colleagues evaluated 791 randomized controlled trials (RCTs) […]